Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 6, 2001, Pages 614-617

  Martoni, Andrea ^a   Di Fabio, Francesca ^a   Guaraldi, Monica ^a   Piana, Edera ^a   Ramini, Remo ^a   Lelli, Giorgio ^b   Palomba, Giuseppe ^b   Artioli, Fabrizio ^c   Bandieri, Elena ^c   Robustelli Della Cuna, Gioacchino ^d   Preti, Pietro ^d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c Ospedale Ramazzini   (Italy)

^d IRCCS   (Italy)

Author keywords

Elderly patients; Gemcitabine; NSCLC; Toxcility

Indexed keywords

AMINOTRANSFERASE; GEMCITABINE; LIVER ENZYME;

AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG TOLERABILITY; EDEMA; ELDERLY CARE; ERYTHEMA; FEMALE; FEVER; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 0035209532     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200112000-00018     Document Type: Article

References (11)

1. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study
2. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer
3. Synthesis of 2-deoxy-2′,2′-difluoro-D-ribose and 2 deoxy-2′,2′-difluoro -D-ribofuranosyl nucleosides
4. Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: A review
5. Clinical benefit from palliative chemotherapy in non-small cell lung cancer extends to the elderly and those with poor prognostic factors
6. Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: A phase II study
7. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: A phase 2 study
8. Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study
9. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer
10. Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer